Objective: To investigate the relationship between CD4 + CD25 + CD127 dim regulatory T cells (Tregs) and immune imbalance in acquired severe aplastic anemia (SAA). 
Introduction
Severe aplastic anemia (SAA) is a rare disease characterized by severe pancytopenia and bone marrow failure. Recent studies confirmed that aplastic anemia (AA) is an immunemediated disease characteristic of hematopoietic cells destroyed by activated T lymphocytes [1, 2, 3] . Activated suppressor T lymphocytes are markedly increased in SAA patients and suppress normal hematopoiesis in vitro. In addition, suppressive cytokines produced by activated T lymphocytes also play a vital role in the pathogenesis of bone marrow failure. High levels of suppressive cytokines indicate an excessive Th1 type of T cell response. Recent studies have shown that myeloid dendritic cells (DCs), which also expressed high levels of costimulatory molecules (CD86), were increased in AA and were associated with disease severity. This could explain why naive T cells are prone to differentiating into Th1 cells [4] . Furthermore, CD4 + CD25 + FOXP3 + regulatory T cells (Tregs) were decreased at presentation in almost all patients with AA, and a defect in Tregs might explain the increased autoreactive T cells and the development of an AA phenotype [5] .
Tregs are a suppressive subset of T cells, which are essential for maintaining appropriate immune self-tolerance and balance. The main function of Tregs is their powerful capacity to suppress T effector or memory cell activation as well as to regulate self-reactive T cells [6] . Clinical studies have demonstrated a decreased suppressive ability and quantity of Tregs in patients with autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis [7, 8] . Previous studies from our group and others suggested that CD4 + CD25 + Tregs were decreased in untreated SAA patients compared with recovery patients and normal controls [9, 10] . However, CD25 is not a unique Treg marker because it is also present on activated T cells. Recently, studies proposed that low expression of CD127 coexpressed with Foxp3 and CD25, particularly in humans, could be used to distinguish Tregs from activated CD4 + T cells [11] .
In this study, we focused on detecting the quantity of Tregs in SAA, which is considered an autoimmune disease, and we analyzed the relationship between Tregs and the severity of disease as well as T cell subset and DC subset.
Materials and Methods

Study Subjects
A total of 44 patients with SAA were enrolled in this study, including 25 untreated cases and 19 cases in remission after immunosuppressive therapy. All were inpatients of the Hematology Department of Tianjin Medical University General Hospital, China, from January 2013 to October 2013. The diagnosis of SAA was based on International AA Study Group criteria [2] . Patients were excluded if they had Tables 1, 2 , and 3. Twenty-three healthy controls with a median age of 33 years (range: 21-50) were also enrolled in this study, including 6 males and 17 females. The study was approved by the Ethics Committee of Tianjin Medical University, China. Informed written consent was obtained from all patients or their parents in accordance with the Declaration of Helsinki.
Monoclonal Antibodies
CD4-PE, CD25-FITC, CD127-APC, FITC-lineage-cocktail (CD3, CD14, CD16, CD19, CD20, CD56), HLA-DR-PerCP, CD123-PE, CD11c-APC, CD3-PE-Cy5, CD4-FITC, CD8-PE, mouse isotype controls, and lysis solution were purchased from Becton Dickinson (Franklin Lakes, NJ, USA).
Measurement of Quantities of Tregs from Peripheral Blood
CD4 + CD25 + CD127 dim Tregs were identified by singleplatform 3-color flow cytometric analysis. Fresh blood samples of 200 μL processed by ethylenediaminetetraacetic acid were separated into 2 TruCount tubes (Becton Dickinson) and stained with mouse IgG1-PE, mouse IgG1-FITC, and mouse IgG1-APC as a negative control, or with CD4-PE, CD25-FITC, and CD127-APC. After incubation in the dark for 20 min at 4 °C, cells were incubated with 1 mL of lysis solution (Becton Dickinson) for 10 min at room temperature and washed 3 times with phosphate buffered saline. Each specimen was acquired on a FACS-Calibur flow cytometer and analyzed using CellQuest 3.1 software (Becton Dickinson).
Measurement of T Cell Subsets and Dendritic Cell Subsets in Peripheral Blood
CD3 + CD4 + and CD3 + CD8 + T lymphocytes were stained with CD3-PE-Cy5, CD4-FITC, and CD8-PE. Myeloid DC (DC1) was identified as lineage(-)HLA-DR(+)CD11c(+), while plasmacytoid DC (DC2) was identified as lineage(-) HLA-DR(+)CD123(+). DC1 and DC2 were stained with FITClineage-cocktail, HLA-DR-PerCP, CD123-PE, and CD11c-APC. Further staining followed the protocol described above.
Statistical Analysis
Statistical analysis was performed by parametric t-test. Correlation studies were performed by Spearman analysis. A value of p<0.05 was considered statistically significant.
Results
Decreased Numbers of Tregs in Untreated Severe Aplastic Anemia Compared with Healthy Controls
The percentage of CD4 + CD25 + CD127 dim Tregs in peripheral blood lymphocytes (PBLs) was 0.83±0.44% in untreated SAA patients, 2.91±1.24% in recovery patients, and 2.18±0.55% in normal controls. The percentage of CD4 + CD25 + CD127 dim Tregs in PBLs in untreated SAA patients was lower than in recovery patients and normal controls (p<0.05), and there was no statistical difference between recovery patients and normal controls (p>0.05). The percentage of CD4 + CD25 + CD127 dim in CD4 + T cells in recovery patients (9.39±3.51%) was higher than in untreated patients (7.61±5.3%) and normal controls (6.83±1.4%) (p<0.05), and there was no statistical difference between recovery patients and normal controls (p>0.05). The percentage of CD4 + T cells in PBLs from untreated patients (13.55±7.37%) was lower than in recovery patients (31.82±8.43%) and normal controls (32.12±5.88%) (p<0.05), while there was no statistical difference between recovery patients and normal controls (p>0.05) (Figure 1 ).
T Cell Subsets and Dendritic Cell Subsets Were Altered in Severe Aplastic Anemia Patients
T cell subset (CD4 + /CD8 + ratio) was 0.41±0.24 in untreated SAA patients, which was significantly lower than in recovery patients (1.2±0.4) and normal controls (1.11±0.23) (p<0.05). There was no difference between recovery patients and normal controls (p>0.05). DC subset (myeloid DC/ plasmacytoid DC ratio, DC1/DC2 ratio) was 3.08±0.72 in untreated SAA patients, which was significantly higher than in recovery patients (1.61±0.49) and normal controls (1.39±0.36) (p<0.05). There was no difference between recovery patients and normal controls (p>0.05) (Figure 2 ). 
Correlations between CD4 + CD25 + CD127 dim Tregs and T Cell Subsets, Dendritic Cell Subsets, Granulocytes, and RET% in Severe Aplastic Anemia Patients
The percentage of CD4 + CD25 + CD127 dim Tregs in PBLs (CD4 + CD25 + CD127 dim Tregs/PBL) was significantly and positively associated with T cell subset (r=0.955, p<0.01). However, CD4 + CD25 + CD127 dim Tregs/PBL was negatively associated with DC subset (r=-0.765, p<0.01). There were positive correlations between CD4 + CD25 + CD127 dim Tregs/ PBL and granulocyte counts and RET% (r=0.739 and r=0.749, respectively, p<0.01). There was no significant correlation between CD4 + CD25 + CD127 dim Tregs/PBL and hemoglobin and platelets (Figure 3 ).
Discussion
Tregs are considered to play a key role in the mechanisms of peripheral immune tolerance. Tregs use various mechanisms such as cell-to-cell contact and secretion of soluble factors to suppress immune responses. There are several specific mechanisms included, such as the release of inhibitory cytokines and immunosuppressive adenosine; inhibition of IL-2 secretion; perforin-or granzyme-dependent cytolysis of effector cells; and down-regulation of antigen present cell (APC) function via costimulation with CTLA-4 [12] . There are 2 types of Tregs: natural Tregs (nTregs), which develop in the thymus, and induced Tregs (iTregs), which differentiate from naive CD4 + T cells in the periphery. Foxp3 is the most specific marker of nTregs and is critical for the development and maintenance of the suppressive function of Tregs. However, Foxp3 is expressed in the nucleus of Tregs, and therefore it cannot be used to identify nTregs during isolating and purification. It was recently shown that CD127, a specific Treg surface marker, is inversely correlated with Foxp3 expression and the suppressive capacity of nTregs [13] . In the current study, we used the characteristics of constitutively high expression of CD25 and diminished expression of CD127 to discriminate Tregs from conventional CD4 + T cells.
Cellular immunity is abnormal in SAA patients. Numerous studies have shown that both the quantity and the function of myeloid DCs are increased, that Th1 cells are excessively activated along with excessive secretion of Th1-type cytokines, that the ratio of CD4 + /CD8 + T lymphocytes is decreased, and that cytotoxic T cells are over activated [1, 4] . Currently, the consensus is that acquired AA is an autoimmune disease. AA pathogenesis is thought to involve damage to hematopoietic stem/progenitor cells by autoreactive T lymphocytes activated by Th1 cells. An important question is why these autoreactive T cells are not suppressed and removed by selftolerance. Furthermore, what is the influence of Tregs on the complex pathogenesis of AA? Our results demonstrated that the percentage of CD4 + CD25 + CD127 dim Tregs in the peripheral blood was decreased in SAA patients. Furthermore, the percentage of CD4 + CD25 + CD127 dim Tregs increased and was restored to normal levels in the patients after intensive immunosuppressive therapy. Additionally, in SAA patients with a more serious condition, we noted that their granulocyte counts and RET% were markedly decreased, DC1 and DC1/DC2 ratios were increased, CD4 + /CD8 + ratios were decreased, and Tregs were decreased. After statistical analysis, we concluded that the percentage of CD4 + CD25 + CD127 dim Tregs in PBLs was negatively associated with DC subset and positively associated with T cell subset, granulocyte counts, and RET%. These results suggested that Tregs were showed that Tregs from patients with autoimmune diseases could be purified, activated, and expanded similarly to those from healthy donors. Additionally, ex vivo expanded Tregs showed enhanced suppressive functions compared with Tregs freshly purified from the same patients [15] . Studies using murine models confirmed that Treg adoptive transfer is feasible and efficient for treating autoimmune disease [16] . Taken together, these studies suggest that new therapeutic strategies based on Tregs for the treatment of SAA might be beneficial.
